Overview

Phase II Study to Evaluate MAintenance Therapy With Olaparib or Selumetinib Plus Durvalumab According to BRCAness and KRAS Somatic Status Personalized in Metastatic Pancreatic Adenocarcinoma Patients

Status:
Recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

MAZEPPA is open-label, phase II study to assess the efficacy of a genomic-driven maintenance therapy in terms of PFS in Pancreatic ductal adenocarcinoma (PDAC) patients with disease controlled after 4 months of mFOLFIRINOX chemotherapy as following: Patients with a BRCAness somatic profile: olaparib Arm A. Patients with no BRCAness profile and with KRAS mutation randomization between durvalumab plus selumetinib Arm B, versus FOLFIRI Arm C.

Phase:

Phase 2

Details

Lead Sponsor:

GERCOR - Multidisciplinary Oncology Cooperative Group

Collaborator:

AstraZeneca

Treatments:

Durvalumab
Olaparib